Section
Money
Earnings analysis, pricing strategy, and financial dynamics
MoneyBioPharma Dive ↗
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …
MoneyFierceBiotech ↗
If any proof was needed that big money is still available for AI drug development, look no further than the 10…
MoneyFiercePharma ↗
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…
MoneyFierceBiotech ↗
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…
MoneyFiercePharma ↗
Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to…
MoneyBriefing
Vancouver’s Optimi Health launched a 2.5M-share IPO just as U.S. policy momentum boosts psychedelics research,…
Page 1
Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.